A new report found that while more than 90% of health systems have deployed third-party AI tools, less than half have the ...

Six months after withdrawing a drug from the U.S. market for a rare liver disease, Alfasigma is reaffirming its commitment to the disorder by paying $300 million for rights to a GSK drug candidate on ...

Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal ...

When the healthcare system defaults to uncertainty, people delay care because it feels safer for their wallets. In some cases ...

Roivant Sciences subsidiary Priovant Therapeutics received FDA approval for Lisraya as a treatment for the rare inflammatory ...

AstraZeneca and Amgen drug Tezspire met the goals of a Phase 3 test in eosinophilic esophagitis (EoE), a chronic disorder ...

SCAN is a non-profit Medicare Advantage insurer serving 460,000 members across California, Arizona, Nevada, Texas, New Mexico ...

Epic faced an FTC antitrust probe this week, but that didn't stop the EHR giant from unveiling a wave of new AI tools at its ...

Employers expect healthcare costs to rise 9.2% in 2027 as they seek ways to curb rising hospital and pharmacy costs.

Onos Health's Series A funding round was led by Costanoa, with support from Flare Capital Partners and CVS Health Ventures.

Merck and Moderna said intismeran autogene, an mRNA cancer vaccine that prompts an immune response to proteins expressed by a ...

FDA approval of Revolution Medicines’ daraxonrasib, brand name Rasonque, makes the molecule the first RAS inhibitor approved ...